Abstract 1603
Background
The responses and benefit from targeted therapies in gastric cancer (GC) remain limited and improved biologic understanding is needed. Both inter-tumoral and intra-tumoral heterogeneity for HER2 and EGFR has been observed in small datasets and may limit efficacy of targeted therapies. Broader heterogeneity assessment has not been studied. We sought to explore intra-tumoral heterogeneity in GC by multi-region sampling of primary gastric tumors with subsequent interrogation of mutational differences via next generation sequencing (NGS) and cell-free DNA (cfDNA) analyses.
Methods
Patients with newly diagnosed advanced GC underwent endoscopic mapping and pre-determined 8-region biopsy of the primary with concurrent plasma cfDNA sampling. Biopsy samples were subjected to NGS using a 32-gene custom panel and plasma cfDNA analyzed via 28-gene cfDNA assay. Clinicopathologic features and genomic alterations (GA) were abstracted and descriptive statistics were used to compare samples.
Results
All six initial patients underwent multi-region biopsy and NGS. Within a given patient the average number of GA observed in all biopsies (shared GA) was 3.3 with an average of 12.8 non-shared alterations (p = < 0.05). There was no significant difference in the average mutant allele frequency (MAF) or MAF variability between shared and non-shared GA in the primary tumor (p = > 0.05). Cell free DNA analyses identified GA not found in each respective case’s multi-region primary tumor analysis, likely reflective of GA derived from metastatic sites. An updated cohort will be presented.
Conclusions
Endoscopic multi-region biopsy of GC is feasible and significant genomic heterogeneity existed within the primary in all patients. Paired cfDNA analyses should also be included to complement studies of intra-tumoral heterogeneity. Standardized methods to determine intra and inter-tumoral heterogeneity are needed and stratification by heterogeneity score in prospective trials may inform optimal patient selection, particularly in targeted therapies.
Clinical trial identification
Legal entity responsible for the study
Samsung Medical Center.
Funding
Samsung Medical Center.
Editorial Acknowledgement
Disclosure
S.J. Klempner: Consulting, Advisory: Lilly Oncology, Boston Biomedical, Astellas, Merck. J. Chao: Consulting, Advisory: Boston Biomedical, Merck, Five Prime Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
5720 - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH+) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)
Presenter: Septelia Wanandi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4844 - Estrogen-related receptor _ as a potential molecular target for endometrial cancer therapy
Presenter: TETSUYA KOKABU
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1200 - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies
Presenter: Jacques Gaudreault
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2905 - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma
Presenter: Anne Jouinot
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2597 - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
Presenter: Juan Manuel O'Connor
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2663 - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Presenter: Julien Taieb
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1670 - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
Presenter: Takeshi Kawakami
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1088 - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Presenter: thomas Aparicio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2548 - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer
Presenter: Toshiki Masuishi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3244 - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis
Presenter: Katerina Kopeckova
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract